Published in J Exp Med on January 01, 1990
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol (1990) 3.54
Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med (2002) 2.89
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol (1992) 2.83
Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med (1997) 2.76
Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci U S A (1991) 2.61
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 2.34
Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev (2011) 2.22
Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol (1992) 2.14
T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med (1994) 2.04
Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev (1995) 1.90
Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med (1996) 1.85
An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants. J Virol (1990) 1.79
Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci U S A (1990) 1.74
Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection. J Virol (1992) 1.64
T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med (1995) 1.56
Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol (1992) 1.55
Latent antigen vaccination in a model gammaherpesvirus infection. J Virol (2001) 1.45
Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol (1991) 1.41
Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. Immunology (1991) 1.30
Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci U S A (1992) 1.28
Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol (2007) 1.28
Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J Clin Invest (2005) 1.26
Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med (1995) 1.25
Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc Natl Acad Sci U S A (1991) 1.20
Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals. J Virol (1996) 1.17
X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol (1999) 1.15
Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. J Exp Med (1996) 1.15
Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer (1995) 1.13
Infection of human endothelial cells with Epstein-Barr virus. J Exp Med (1995) 1.10
T cell-T cell killing is induced by specific epitopes: evidence for an apoptotic mechanism. J Exp Med (1991) 1.08
Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transplant Sci (1994) 1.06
Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. J Virol (1993) 1.05
Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize immediate-early protein ICP27. J Virol (1991) 1.04
The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci (2001) 1.04
Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences. J Virol (1996) 0.99
Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. J Virol (1998) 0.98
T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med (2005) 0.93
T-cell memory: lessons from Epstein-Barr virus infection in man. Philos Trans R Soc Lond B Biol Sci (2000) 0.92
Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer (2016) 0.88
Failure of Epstein-Barr virus-specific cytotoxic T lymphocytes to lyse B cells transformed with the B95-8 strain is mapped to an epitope that associates with the HLA-B8 antigen. Clin Exp Immunol (1992) 0.82
Is the Epstein-Barr virus EBNA-1 protein an oncogen? Proc Natl Acad Sci U S A (2009) 0.80
Progress, prospects, and problems in Epstein-Barr virus vaccine development. Curr Opin Virol (2014) 0.79
Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy. Am J Pathol (2002) 0.78
Antigen(s)-specific tumour-infiltrating lymphocytes from tumour induced by human herpes virus-6 (HHV-6) DNA transfected NIH 3T3 transformants. Clin Exp Immunol (1991) 0.78
Infectious Mononucleosis. Curr Top Microbiol Immunol (2015) 0.77
Cytolytic T lymphocytes from HLA-B8+ donors frequently recognize the Hodgkin's lymphoma associated latent membrane protein 2 of Epstein Barr virus. Herpesviridae (2011) 0.77
Cytotoxic T-lymphocyte clones specific for an immunodominant epitope display discerning antagonistic response to naturally occurring Epstein-Barr virus variants. J Virol (1996) 0.77
Analysis of the tumorigenic potential of common marmoset lymphoblastoid cells expressing a constitutively activated c-myc gene. Br J Cancer (1993) 0.76
General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci U S A (1985) 8.77
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A (1984) 5.27
T-cell antigenic sites tend to be amphipathic structures. Proc Natl Acad Sci U S A (1985) 5.05
Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature (1988) 2.85
Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res (1981) 2.74
Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med (1988) 2.52
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer (1984) 2.14
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A (1987) 1.77
New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol (1987) 1.58
Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus. Virology (1989) 1.35
Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein. Proc Natl Acad Sci U S A (1987) 1.28
A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet (1995) 4.95
Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol (1997) 4.65
A Barycentremetric study of the sagittal shape of spine and pelvis: the conditions required for an economic standing position. Ann Biomed Eng (1992) 4.00
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature (1988) 2.85
Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer (1978) 2.81
Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res (1981) 2.74
Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem (1994) 2.62
Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med (1994) 2.47
Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res (1993) 2.29
spa Typing of Staphylococcus aureus as a frontline tool in epidemiological typing. J Clin Microbiol (2007) 2.24
Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet (1996) 2.20
Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol (1972) 2.18
HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer (1984) 2.14
Standardization of Cystatin C: development of primary and secondary reference preparations. Scand J Clin Lab Invest Suppl (2008) 2.11
An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med (1994) 2.02
The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur J Immunol (1992) 1.98
Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. J Biol Chem (2001) 1.96
Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology (2001) 1.93
The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract. Aliment Pharmacol Ther (2009) 1.92
Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev (1995) 1.90
Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res (2001) 1.88
Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res (1990) 1.84
Accurate sequencing by hybridization for DNA diagnostics and individual genomics. Nat Biotechnol (1998) 1.83
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A (1999) 1.82
An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants. J Virol (1990) 1.79
Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci U S A (1990) 1.74
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol (2003) 1.68
Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn (2001) 1.67
Cryptococcal disease presenting as cellulitis. Clin Infect Dis (1992) 1.63
Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer (1985) 1.62
Quality of life following radical surgical treatment of gastric carcinoma. World J Surg (1999) 1.61
HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc Natl Acad Sci U S A (1980) 1.60
Trendelenburg positioning after cardiac surgery: effects on intrathoracic blood volume index and cardiac performance. Eur J Anaesthesiol (2003) 1.59
Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis (1998) 1.58
New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol (1987) 1.58
HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity (1998) 1.58
MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene (2011) 1.57
T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med (1995) 1.56
Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol (1998) 1.53
Long-term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T cells in virus-infected leukocyte cultures. Int J Cancer (1979) 1.51
Thoracic, but not lumbar, epidural anesthesia improves cardiopulmonary function in ovine pulmonary embolism. Anesth Analg (2001) 1.50
Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis. J Intern Med (2008) 1.49
Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther (2012) 1.47
In vitro chamber specification during embryonic stem cell cardiogenesis. Expression of the ventricular myosin light chain-2 gene is independent of heart tube formation. J Biol Chem (1993) 1.45
Partial purification of the Epstein-Barr virus nuclear antigen(s). J Biol Chem (1983) 1.44
Long-term effects of a perioperative safety checklist from the viewpoint of personnel. Acta Anaesthesiol Scand (2012) 1.44
Misexpression of Cwnt8C in the mouse induces an ectopic embryonic axis and causes a truncation of the anterior neuroectoderm. Development (1997) 1.43
Ex situ resection of primary cardiac tumors. Thorac Cardiovasc Surg (2003) 1.42
Cutaneous lupus erythematosus-treatment with pulsed dye laser. Br J Dermatol (1999) 1.41
The mouse brain transcriptome by SAGE: differences in gene expression between P30 brains of the partial trisomy 16 mouse model of Down syndrome (Ts65Dn) and normals. Genome Res (2000) 1.40
Wnt pathway regulation in chronic renal allograft damage. Am J Transplant (2009) 1.39
[Peri-ungual capillaroscopy. Value in the diagnosis of systemic diseases]. Presse Med (1993) 1.39
Continuous autotransfusion in a Jehovah's witness undergoing coronary artery bypass grafting. Anesth Analg (1999) 1.39
Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int J Cancer (1984) 1.37
Allogeneic stimulation modulates the in vitro response of T cells to transplantation antigen. Nature (1974) 1.37
Early evolution of cytochrome bc complexes. J Mol Biol (2000) 1.36
Functional analysis of Sox10 mutations found in human Waardenburg-Hirschsprung patients. J Biol Chem (1998) 1.36
Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus. Virology (1989) 1.35
Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol (1994) 1.35
The structure of the gene coding for the mouse cell adhesion molecule uvomorulin. Nucleic Acids Res (1991) 1.34
Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J Immunol (1997) 1.34
Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis. J Virol (1984) 1.32
Tissue engineering of bone: effects of mechanical strain on osteoblastic cells in type I collagen matrices. Biomaterials (2005) 1.32
Diagnosis and treatment of nonocclusive mesenteric ischemia after open heart surgery. Ann Thorac Surg (2001) 1.32
Radical resection of cardiac sarcoma. Thorac Cardiovasc Surg (2004) 1.31
Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro. Eur J Immunol (1981) 1.30
Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. Immunology (1991) 1.30
Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus. J Virol (1997) 1.28
Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J Virol (1996) 1.27
Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis (1990) 1.26
Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J Virol (1997) 1.25
Simple and efficient production of embryonic stem cell-embryo chimeras by coculture. Proc Natl Acad Sci U S A (1993) 1.25
Evidence for two classes of chromatin-associated Epstein-Barr virus-determined nuclear antigen. J Virol (1982) 1.25
A meta-analysis of quantitative trait loci associated with body weight and adiposity in mice. Int J Obes (Lond) (2006) 1.24
Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol (1998) 1.21
Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol (1997) 1.20
hMSH5: a human MutS homologue that forms a novel heterodimer with hMSH4 and is expressed during spermatogenesis. Cancer Res (1999) 1.20
Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc Natl Acad Sci U S A (1991) 1.20